CLLKF Stock Chart & Stats
$1.98
$0.10(3.47%)
At close: 4:00 PM EST
$1.98
$0.10(3.47%)
Day’s Range― - ―
52-Week Range$1.48 - $4.14
Previous CloseN/A
Volume500.00
Average Volume (3M)167.00
Market Cap
$108.48M
Enterprise Value$1.05B
Total Cash (Recent Filing)$744.30M
Total Debt (Recent Filing)$690.60M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 19, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.97
Shares Outstanding69,074,900
10 Day Avg. Volume250
30 Day Avg. Volume167
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market Cap9.68
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit1.57
Enterprise Value/Ebitda-0.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$168.32M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables, Software, And Service RevenueBICO’s business model pairs capital instrument sales with follow-on consumables, software subscriptions and service contracts. That installed-base driven recurring mix supports steadier revenue per customer over time, enabling higher lifetime value and cross-sell leverage versus one-off equipment sales.
Improving Gross Margins And Currently Positive Operating Cash FlowA sustained uplift in gross margin alongside positive operating cash flow indicates improving operational efficiency and some ability to self-fund activities. If maintained, these trends create durable capacity to invest in product development and support the installed base without immediate external financing.
Moderate Leverage With Debt Below EquityWith debt below equity and a debt-to-equity near 0.86, the company carries moderate leverage versus high-risk peers. This structural position provides some financial flexibility to manage working capital and cyclical swings, reducing default risk compared with highly leveraged biotech hardware peers.
Bears Say
Very Large Negative Net Margins And LossesPersistent, deep net losses mean the business has not translated margin improvement into profitability. Over months, such sustained negative margins erode retained earnings, limit reinvestment capacity and increase reliance on external capital, challenging long-term viability if profitability isn't achieved.
Materially Declined Equity Base Reduces FlexibilityA materially smaller equity base weakens the firm’s shock absorption and makes future fundraising more dilutive or costly. Structurally, reduced equity limits strategic optionality for M&A, capex or R&D and raises governance and solvency risk during prolonged revenue weakness.
Volatile And Falling Free Cash FlowSharp FCF deterioration and historical inconsistency signal execution risk in converting sales to durable cash. Over several months this undermines the company’s capacity to fund growth, service debt or sustain R&D, increasing the probability of future financing needs under adverse conditions.
BICO Group AB Class B News
CLLKF FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was $1.48 and its highest was $4.14 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is $108.48M.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Aug 19, 2026 which is in 41 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Apr 29, 2026. The company reported -$0.178 earnings per share for the quarter, missing the consensus estimate of -$0.103 by -$0.075.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.08.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -$0.178 in its last earnings report, missing expectations of -$0.103. Following the earnings report the stock price went up 10.243%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in CLLKF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
CLLKF Company Deck
CLLKF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company executed its strategic repositioning (BICO 2.0), strengthened its cash position through a EUR 40m bond issuance, reduced debt and demonstrated a clear Q4 recovery with strong margins and Biosero momentum. However, full-year financials were weak (organic sales -8%, adjusted EBITDA only SEK 5m, Lab Automation full-year decline -26% and negative EBITDA), and the business faced notable macro headwinds (US academia funding cuts, FX pressure and cautious CapEx). Product launches, partnerships and AI-enabled offerings provide a foundation for growth, but near-term performance still reflects industry and legacy operational challenges.View all CLLKF earnings summariesTechnical Analysis
CellaVision AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.56% Other Institutional Investors
95.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---